Literature DB >> 12457384

What does the Edinburgh high-risk study tell us about schizophrenia?

Eve C Johnstone1, Stephen M Lawrie, Richard Cosway.   

Abstract

The Edinburgh High Risk Study concerns 162 young people aged 16 to 25 at ascertainment who have at least two close relatives with schizophrenia. They are compared with two control groups (1) of age-matched well subjects and (2) of age-matched subjects with first schizophrenic episodes. The interim results show that schizophrenia has developed in 10 high-risk subjects and no controls and that all categories of psychopathology are more marked in the high-risk subjects. Psychopathology shows no relationships with measures of genetic liability. Neuropsychological measures are most impaired in the individuals with first-episode schizophrenia, with high-risk subjects performing better and well controls better still. The greater the genetic liability of the high-risk subjects, the poorer the neuropsychological performance. Neuropsychological impairments occurred in more high-risk subjects than are expected to develop schizophrenia. Structural brain scans show significant differences between those with first-episode schizophrenia, high-risk subjects, and well controls. Brain structure is related to genetic liability in that high-risk subjects with higher genetic liability have smaller right and left prefrontal lobes and smaller right and left thalami. In those high-risk subjects with two scans, there was a significantly greater reduction in temporal lobe size in those with psychotic symptoms than in those without. It is suggested that in high-risk subjects, the change from vulnerability to psychosis may be preceded by reduction in size and deteriorating function of the temporal lobe. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12457384     DOI: 10.1002/ajmg.b.10304

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

1.  Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia.

Authors:  Eric C Zimmerman; Mark Bellaire; Samuel G Ewing; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-05-08       Impact factor: 7.853

2.  Specificity of familial transmission of schizophrenia psychosis spectrum and affective psychoses in the New England family study's high-risk design.

Authors:  Jill M Goldstein; Stephen L Buka; Larry J Seidman; Ming T Tsuang
Journal:  Arch Gen Psychiatry       Date:  2010-05

3.  Grey matter and cognitive deficits in young relatives of schizophrenia patients.

Authors:  Tejas S Bhojraj; Alan N Francis; Debra M Montrose; Matcheri S Keshavan
Journal:  Neuroimage       Date:  2010-03-31       Impact factor: 6.556

Review 4.  Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress.

Authors:  Anthony A Grace
Journal:  Neurotox Res       Date:  2010-02-09       Impact factor: 3.911

5.  Progressive alterations of the auditory association areas in young non-psychotic offspring of schizophrenia patients.

Authors:  Tejas S Bhojraj; John A Sweeney; Konasale M Prasad; Shaun Eack; Rajaprabhakaran Rajarethinam; Alan N Francis; Debra M Montrose; Matcheri S Keshavan
Journal:  J Psychiatr Res       Date:  2010-06-11       Impact factor: 4.791

Review 6.  Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia.

Authors:  Anthony A Grace
Journal:  Neuropharmacology       Date:  2011-05-23       Impact factor: 5.250

Review 7.  Arguments for the sake of endophenotypes: examining common misconceptions about the use of endophenotypes in psychiatric genetics.

Authors:  David C Glahn; Emma E M Knowles; D Reese McKay; Emma Sprooten; Henriette Raventós; John Blangero; Irving I Gottesman; Laura Almasy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2014-01-24       Impact factor: 3.568

8.  Premorbid cognitive deficits in young relatives of schizophrenia patients.

Authors:  Matcheri S Keshavan; Shreedhar Kulkarni; Tejas Bhojraj; Alan Francis; Vaibhav Diwadkar; Debra M Montrose; Larry J Seidman; John Sweeney
Journal:  Front Hum Neurosci       Date:  2010-03-09       Impact factor: 3.169

Review 9.  The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia?

Authors:  Lynn E DeLisi
Journal:  Curr Opin Psychiatry       Date:  2008-03       Impact factor: 4.741

Review 10.  Understanding structural brain changes in schizophrenia.

Authors:  Lynn E DeLisi; Kamila U Szulc; Hilary C Bertisch; Magda Majcher; Kyle Brown
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.